Chronic angiotensin IV
treatment reverses endothelial dysfunction in ApoE-deficient mice.
Leucyl/cystinyl aminopeptidase (LNPEP) is a catalyst in the final step of conversion of angiotensinogen to angiotensin IV
. Leucyl/cystinyl aminopeptidase also cleaves vasopressin, oxytocin, bradykinin, and other peptide hormones .
First, various site products such as angiotensin IV
can be formed specifically in the presence of ACE inhibition or angiotensin receptor blockade and they activate mas receptors.
Harding and College of Arts and Sciences Professor Jay Wright, have been working on their compound since 1992, when they started looking at the impact of the peptide angiotensin IV
on the hippocampus, a brain region involved in spatial learning and short-term memory.